University of Chicago phase II consortium trial of selumetinib (MEKi) demonstrates low tolerability and efficacy in relapsed DLBCL

作者:Galanina Natalie*; Smith Sonali M; Liao Chuanhong; Petrich Adam; Libao Bernadette; Gartenhaus Ronald; Westin Jason R; Cohen Kenneth S; Knost James A; Stadler Walter M; Doyle Austin; Karrison Theodore; Gordon Leo I; Evens Andrew M
来源:British Journal of Haematology, 2018, 181(2): 264-267.
DOI:10.1111/bjh.14544